Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY
Sponsor: Cancer and Leukemia Group B
Listed as NCT00002819, this PHASE3 trial focuses on Ovarian Cancer and remains terminated or withdrawn. Sponsored by Cancer and Leukemia Group B, it has been updated 8 times since 1996, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
May 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Feb 2021 — May 2023 [monthly]
Terminated PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Nov 1996
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer and Leukemia Group B
- Eastern Cooperative Oncology Group
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baltimore, United States, Birmingham, United States, Boston, United States, Buffalo, United States, Burlington, United States, Chapel Hill, United States, Charleston, United States, Chicago, United States, Columbia, United States, Des Moines, United States and 34 more location s